Cargando…

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner

Detalles Bibliográficos
Autores principales:	Campani, Claudia, Rimassa, Lorenza, Personeni, Nicola, Marra, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729316/ https://www.ncbi.nlm.nih.gov/pubmed/33313277 http://dx.doi.org/10.21037/atm-20-3788

Ejemplares similares

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Novel Therapies for Hepatocellular Carcinoma
por: Rimassa, Lorenza
Publicado: (2020)

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2020)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Targeting Angiogenesis for Advanced Hepatocellular Carcinoma
por: Eso, Yuji
Publicado: (2020)

Approach to systemic therapy in advanced hepatocellular carcinoma
por: Sankar, Kamya, et al.
Publicado: (2022)

Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure
por: Kim, Nalee, et al.
Publicado: (2022)

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
por: Personeni, Nicola, et al.
Publicado: (2021)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Challenges of advanced hepatocellular carcinoma
por: Colagrande, Stefano, et al.
Publicado: (2016)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review
por: Vogel, Arndt, et al.
Publicado: (2023)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
por: Cammarota, Antonella, et al.
Publicado: (2023)

Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
por: Nipp, Ryan, et al.
Publicado: (2016)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Role of liver biopsy in hepatocellular carcinoma
por: Di Tommaso, Luca, et al.
Publicado: (2019)

Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis
por: Risaliti, Matteo, et al.
Publicado: (2022)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
por: Personeni, Nicola, et al.
Publicado: (2020)

Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air
por: Rai, Vikrant, et al.
Publicado: (2022)

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
por: Campani, Claudia, et al.
Publicado: (2023)

An acid trip activates protumoral macrophages to promote hepatocellular carcinoma malignancy
por: Graham, Nicola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q7c6803dvmg9561rq7rip2uv53